(redirected from Revatio)
Also found in: Dictionary, Thesaurus.


disturbance, impairment, or abnormality of functioning of an organ. adj., adj dysfunc´tional.
erectile dysfunction impotence.
minimal brain dysfunction former name for attention-deficit/hyperactivity disorder.
risk for peripheral neurovascular dysfunction a nursing diagnosis accepted by the North American Nursing Diagnosis Association, defined as being at risk for disruption in circulation, sensation, or motion of an extremity or limb.
sexual dysfunction see sexual dysfunction.



sildenafil citrate


Pharmacologic class: Phosphodiesterase type 5 (PDE5) inhibitor

Therapeutic class: Anti-erectile dysfunction agent

Pregnancy risk category B


Inhibits PDE5, enhancing the effects of nitric oxide released during sexual stimulation. This action inactivates cyclic guanosine monophosphate (cGMP), which then increases cGMP levels in corpus cavernosum. Resulting smooth muscle relaxation promotes increased blood flow and subsequent erection. Also relaxes pulmonary vascular smooth muscle cells and, to a lesser degree, vasodilation in systemic circulation.


Injection (Revatio): 10 mg in 12.5-ml single-use vial

Tablets: 20 mg (Revatio); 25 mg, 50 mg, 100 mg (Viagra)

Indications and dosages

Erectile dysfunction

Adults: 50 mg P.O., preferably 1 hour before anticipated sexual activity. Range is 25 to 100 mg taken 30 minutes to 4 hours before sexual activity, not to exceed one dose daily.

Pulmonary hypertension (Revatio only)

Adults: 20 mg P.O. t.i.d. approximately 4 to 6 hours apart, with or without food. Higher doses not recommended. Or, 10 mg by I.V. bolus t.i.d.

Dosage adjustment

• Hepatic or renal impairment (Viagra)

• Concurrent use of hepatic isoenzyme inhibitors (such as cimetidine, erythromycin, itraconazole, ketoconazole) (Viagra)

• Elderly patients (Viagra)


• Hypersensitivity to drug

• Concurrent use of nitrates (nitroglycerin, isosorbide mononitrate or dinitrate)


Use cautiously in:

• serious cardiovascular disease (such as history of myocardial infarction, cerebrovascular accident, or serious arrhythmia within past 6 months); coronary artery disease (current or previous) with unstable angina; resting blood pressure below 90/50 mm Hg or above 170/110 mm Hg (current or previous); heart failure (current or previous); renal or hepatic impairment (current or previous); bleeding disorder; active peptic ulcer; anatomic penile deformity; retinitis pigmentosa; conditions associated with priapism (sickle cell anemia, multiple myeloma, leukemia); pulmonary veno-occlusive disease; use not recommended for any of these conditions

• history of uncontrolled hypertension or hypotension

• concurrent use of alpha blockers and antihypertensives (particularly bosentan)

• concurrent use of potent CYP3A inhibitors such as erythromycin, ketoconazole, itraconazole, ritonavir, or saquinavir (use not recommended)

• patients older than age 65

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


Don't give concurrently with nitrates.

• Administer Viagra 30 minutes to 4 hours before sexual activity.

• If administering Revatio I.V., give by bolus injection only.

Adverse reactions

CNS: headache, dizziness, anxiety, drowsiness, vertigo, transient global amnesia, insomnia, paresthesia, seizures, cerebrovascular hemorrhage, transient ischemic attack

CV: hypertension, hypotension, myocardial infarction (MI), cardiovascular collapse, ventricular arrhythmias, sudden death

EENT: transient vision loss, blurred or color-tinged vision, increased light sensitivity, ocular redness, retinal bleeding, vitreous detachment or traction, photophobia, hearing loss, epistaxis, rhinitis, sinusitis nasal congestion

GI: diarrhea, dyspepsia, gastritis

Musculoskeletal: myalgia

Respiratory: exacerbation of dyspnea

GU: hematuria, urinary tract infection, priapism

Skin: flushing, rash, erythema, pyrexia

Other: hypersensitivity including anaphylactic reactions (rare)


Drug-drug. Alpha blockers, Antihypertensives, nitrates: increased risk of hypotension

Enzyme inducers, rifampin: reduced sildenafil blood level

Hepatic isoenzyme inhibitors (such as cimetidine, erythromycin, itraconazole, ketoconazole), protease inhibitors (such as indinavir, nelfinavir, ritonavir, saquinavir): increased sildenafil blood level and effects

Drug-food. High-fat diet: reduced drug absorption, decreased peak level

Patient monitoring

• Monitor cardiovascular status carefully.

• Evaluate patient's vision and hearing.

• Assess for drug efficacy.

Patient teaching

• Advise patient taking drug for erectile dysfunction to take 30 minutes to 4 hours before sexual activity.

• Tell patient not to exceed prescribed dosage or take more than one dose daily.

Instruct patient to stop sexual activity and contact prescriber immediately if chest pain, dizziness, or nausea occurs.

Teach patient to recognize and immediately report serious cardiac and vision problems and sudden decrease in or loss of hearing.

• Inform patient that drug can cause serious interactions with many common drugs. Instruct him to tell all prescribers he's taking it.

Caution patient never to take drug with nitrates, because of risk of potentially fatal hypotension.

• Instruct patient not to take other PDE5 inhibitors.

• Instruct patient to report priapism (persistent, painful erection) or erections lasting more than 4 hours.

• Tell patient that high-fat diet may interfere with drug efficacy.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.


A selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5); relaxes the muscle in the penis, resulting in greater blood flow and erection; used to treat male impotence; potentiates the hypotensive effects of nitrates.


A drug, C22H30N6O4S, used to treat sexual dysfunction by increasing the level of cyclic GMP, which increases blood flow to erectile tissues.


Medication that relaxes the muscle in the penis, resulting in greater blood flow and erection; used to treat male impotence; potentiates the hypotensive effects of nitrates.


Agent that relaxes muscle in penis, resulting in greater blood flow and erection; used to treat male impotence; potentiates hypotensive effects of nitrates.
References in periodicals archive ?
According to IMS Health, Revatio Tablets, 20mg, had US sales of about USD338.7m for the 12 months ending 30 September 2012.
Revatio is a phosphodiesterase-5 inhibitor approved by the FDA to improve exercise ability and delay the progression of PAH in adults.
"Revatio is not a cure but it does make the condition manageable and without question it improves your quality of life.
The new treatment, which has the same active ingredient as Viagra, has been given a different trade name, Revatio, and is white and round, to differentiate it from the blue diamond-shaped anti-impotence drug.
Patients will be given the drug under the brand name Revatio, and the pills will be white and round, to differentiate it from the blue diamond-shaped anti-impotence drug.
In June, the Food and Drug Administration cleared Viagra's maker, New York-based Pfizer, to market the sildenafil drag called Revatio for the treatment of pulmonary hypertension.
The sanctioned ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) REVATIO (sildenafil citrate) Tablets 20 mg of Pfizer, Inc.
But women who take Revatio for pulmonary hypertension may find their desire for sex increases.
Recent product introductions from Camber include aripiprazoe (Abilify), lamivudine/zidovudine (Combivir), montelukast (Singulair), pantoprazole (Protonix); raloxifene (Evista), rizatriptan (Maxalt); sildenafil (Revatio), valsartan (Diovan) and zolmitriptan (Zomig).
Watson Pharmaceuticals Inc (NYSE: WPI), a global, integrated speciality pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products, announced yesterday that its subsidiary, Watson Laboratories Inc, has received Abbreviated New Drug Application (ANDA) approval for its Sildenafil Tablets, 20 mg, the generic equivalent to Pfizer's Revatio, from the United States Food and Drug Administration.
For example, in the pivotal randomized, placebo-controlled, double-blind crossover trial--Sildenafil Use in Pulmonary Arterial Hypertension (SUPER)--12 weeks of sildenafil (Revatio) at 20 mg t.i.d, resulted in a mean placebo-corrected 45 meter gain in 6-minute walk distance, compared with baseline (N.